Skip to main content

Advertisement

Table 1 Demographic characteristics of the included studies

From: Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials

Author Study design Target Population Treatment duration n Study groups Age, years Female (n, %) BMI, (kg/m2) Total cholesterol (mg/dl) LDL cholesterol (mg/dl) HDL cholesterol (mg/dl) Triglycerides (mg/dl)
Balan et al. (1994) [18] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 2 years 89 Placebo 52 ± 9.4 77 (87) ND 277.5 ± 106.0 ND 60.9 ± 20.3 117.2 ± 70.7
88 UDCA 13–15 mg/kg/day 54 ± 9.3 80 (91) ND 288.3 ± 121.7 ND 63.1 ± 23.6 102.0 ± 50.4
Battezzati et al. (1993) [21] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 6 months 44 UDCA 500 mg/day 54 ± 2 37 (84) ND 263 ± 12 ND 78 ± 6 ND
44 Placebo 55 ± 2 41 (93) ND 266 ± 13 ND 61 ± 5 ND
Braga et al. (2009) [22] Randomized, double-blind, placebo-controlled Primary hypercholeste-rolemia 6 months 57 UDCA 13–15 mg/kg/day ND ND ND 241.1 ± 30 160.2 ± 23 47.7 ± 12 166.0 ± 70
68 Placebo ND ND ND 244.7 ± 29 160.6 ± 19 48.0 ± 12 180.8 ± 96
Carulli et al. (1981) [32] Randomized, double-blind, placebo-controlled Hypertriglyce-ridemia 1 month 8 UDCA 600 mg/day 40.4a 1 (12) ND 266a ND 38a 405a
8 Placebo 40.2a 2 (25) ND 254a ND 39a 249a
Fromm et al. (1983) [23] Randomized, double-blind, placebo-controlled Patients with gallstones 2 years 12 Placebo 55 ± 10.3 10 (82) ND 201 ± 7.6 ND ND 162 ± 30.8
12 UDCA 400 mg/day 56 ± 16.9 8 (67) ND 227 ± 16.5 ND ND 162 ± 20.6
12 UDCA 800 mg/day 55 ± 16.9 6 (50) ND 248 ± 17.7 ND ND 180 ± 32.4
Gianturco et al. (2013) [39] Randomized, double-blind, placebo-controlled NAFLD 1 year 53 ALA 400 mg/day + UDCA 300 mg/day 65 ± 5 23 (43) 30 ± 2.1 203 ± 8 133 ± 9 45 ± 5 123 ± 11
54 ALA 400 mg/day 60 ± 4 25 (46) 29.5 ± 2 208 ± 9 133 ± 10 49 ± 6 128 ± 15
46 UDCA 300 mg/day 62 ± 6 21 (45) 29.7 ± 1.6 209 ± 10 136 ± 11 47 ± 7 127 ± 11
47 Placebo 61 ± 4 23 (48) 29.3 ± 1.3 207 ± 7 138 ± 12 43 ± 8 129 ± 9
Leuschner et al. (2010) [40] Randomized, double-blind, placebo-controlled NASH 18 months 95 UDCA 23–28 mg/kg/day 41.4 (18–71)a 32 (33) ND 148 ± 102 ND ND 208 ± 111
91 Placebo 45.0 (18–73)a 28 (30) ND 162 ± 94 ND ND 202 ± 111
Lindenthal et al. (2002) [33] Randomized, placebo-controlled, cross-over Healthy volunteers 1 month 20 Overall 19–38b 5 (25) ND     
20 UDCA 750 mg/day     186 ± 24 ND ND ND
20 Placebo     186 ± 19 ND ND ND
Méndez-Sánchez et al. (2004) [19] Randomized, double-blind, placebo-controlled NAFLD 6 weeks 14 UDCA 1200 mg/day 39.7 ± 8 14 (100) 34.2 ± 4.2 196.1 ± 36.7 ND ND ND
13 Placebo 37.8 ± 8 13 (100) 33.3 ± 1.6 177.7 ± 29.3 ND ND ND
Miettinen et al. (1995) [20] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 2 years 23 UDCA 12–15 mg/kg/day 50 ± 9 18 (78) 24.1 ± 2.8 250 ± 122 138 ± 39 65 ± 19 ND
22 Placebo 57 ± 14 21 (95) 24.8 ± 3.7 226 ± 76 131 ± 21 51 ± 26 ND
Nakagawa et al. (1977) [37] Randomized, double-blind, placebo-controlled Patients with gallstones 6 months 13 Placebo ND ND ND 196 ± 30 ND ND 120 ± 33
16 UDCA 150 mg/day ND ND ND 192 ± 41 ND ND 110 ± 37
15 UDCA 600 mg/day ND ND ND 193 ± 29 ND ND 143 ± 59
Parés et al. (2000) [34] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 2 years 99 UDCA 14–16 mg/kg/day 57.4 ± 8.9 92 (92) ND 276 ± 89 ND ND ND
93 Placebo 53.5 ± 9.6 87 (93) ND 276 ± 86 ND ND ND
Poupon et al. (1990) [35] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 6 months 70 UDCA 13–15 mg/kg/day 55 ± 11 66 (94) ND 282 ± 73 ND ND ND
68 Placebo 58 ± 9 60 (89) ND 266 ± 65 ND ND ND
Poupon et al. (1993) [38] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 2 years 17 UDCA 13–15 mg/kg/day 55 ± 12 ND ND 289 ± 66 155 ± 52 44 ± 17 93 ± 32
16 Placebo 58 ± 8 ND ND 273 ± 36 134 ± 38 41 ± 14 102 ± 49
Vuoristo et al. (1995) [36] Randomized, double-blind, placebo-controlled Primary biliary cirrhosis 2 years 31 Placebo 57a 27 (87) 24a 278 ± 105 189 ± 84 61 ± 21 106 ± 48
30 UDCA 12–15 mg/kg/day 52a 22 (73) 24a 251 ± 86 158 ± 64 58 ± 42 115 ± 49
  1. Values are expressed as mean ± SD
  2. Abbreviations: ND no data, BMI body mass index, IQR interquartile range
  3. aMean only
  4. bRange